A First-In-Human Study of LY3839840 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

May 22, 2025

Study Completion Date

May 22, 2025

Conditions

Healthy

Interventions

DRUG

LY3839840

Administered orally.

DRUG

Placebo

Administered orally.

DRUG

Midazolam

Administered orally

Trial Locations (2)

Fortrea Clinical Research Unit, Madison

CenExel ACT, Anaheim

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06153355 - A First-In-Human Study of LY3839840 in Healthy Participants | Biotech Hunter | Biotech Hunter